COMPARISON OF IMMUNOHISTOCHEMICAL EXPRESSION OF INSULIN LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) IN BENIGN AND MALIGNANT SALIVARY GLAND TUMORS
DOI:
https://doi.org/10.33279/jkcd.v14i03.609Keywords:
Insulin-like Growth Factor 1 Receptor (IGF-1R), Salivary Glands, Benign Salivary Gland Tumor, Malignant Salivary Gland tumorAbstract
Objectives: To evaluate the difference in immunohistochemical expression of insulin-like growth
factor-1 receptor (IGF-1R) in diagnosed cases of benign and malignant salivary gland tumors.
Materials and Methods: This Comparative Cross-Sectional Study was conducted at the department of Pathology, Peshawar Medical and Dental College, Peshawar. A total of 100 Salivary Gland Tumors from 56 male and 44 female patients were included in the study, with an average age of 43.50 ± 15.21. The Immunohistochemical Expression of Insulin-like Growth Factor 1 Receptor was determined on both benign and malignant salivary gland tumors using the Bio SB Polyclonal IGF-1R antibody (rabbit, BT-AP04398). The collected data were analyzed using SPSS version 25.
Results: For the immunohistochemical expression of IGF-1R on benign and malignant salivary
gland tumors, the Allred Scoring method was utilized. P value of <0.05 was considered significant,
but no positive signifi cance was found between the expression of IGF-1R and salivary gland tumors.
Conclusion: IGF1R expression was positive in various SGTs but no statistically significant difference was seen in multiple histopathological types of benign and malignant SGT
References
Alsanie I, Rajab S, Cottom H, Adegun O, Agarwal R, Jay A. Distribution and Frequency of Salivary Gland Tumours : An International Multicenter Study. Head Neck Pathol [Internet]. 2022;(0123456789):41–5. Available from: https://doi.org/10.1007/s12105-022-01459
Xu Z, Chen M, Zheng S, Chen S, Xiao J, Hu Z, et al. Differential diagnosis of parotid gland tumours : Application of SWI combined with DWI and DCE-MRI. Eur J Radiol [Internet]. 2022;146:110094. Available from: https://doi.org/10.1016/j.ejrad.2021.110094
Shamloo N, Ghanadan A, Hashemiyan FS, Ghorbanpour M. Epidemiologic Characteristics of Salivary Gland Tumors in an Iranian Population. Shiraz E-Medical J. 2021;In Press(In Press).
Valstar MH, de Bakker BS, Steenbakkers RJHM, de Jong KH, Smit LA, Klein Nulent TJW, et al. Immunohistochemical analysis of salivary gland tumors: Application for surgical pathology practice. Med Oral Patol Oral y Cir Bucal [Internet]. 2020;8(4):269–82. Available from: http://dx.doi.org/10.1016/j.jobcr.2014.05.003
Porcheri C, Meisel CT, Mitsiadis TA. Molecular and cellular modelling of salivary gland tumors open new landscapes in diagnosis and treatment. Cancers (Basel). 2020;12(11):1–24.
Suzuki S, Bandoh N, Goto T, Kubota A. A retrospective study of parotid gland tumors at a single institution. 2022;1–9.
Meyer MT, Watermann C, Dreyer T, Ergün S, Karnati S. 2021 Update on Diagnostic Markers and Translocation in Salivary Gland Tumors. Int J Mol Sci. 2021;22(13).
Kasprzak A, Szafl arski W. Role of alternatively spliced messenger RNA (mRNA) isoforms of the insulin-like growth factor 1 (IGF1) in selected human tumors. Vol. 21, International Journal of Molecular Sciences. 2020. 1–33 p.
Hua H, Kong Q,Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: A challenge for cancer therapy. J Hematol Oncol. 020;13(1):1–17.
Emamverdizadeh P, S VH, Farnia S, Gavgani B, V DM, Lotfi R. Asian Journal of Pharmaceutical Technology & Innovation. 2016;04(18):139–45.
Arslan I, Keles E, Ozercan IH, Tokdemir M, Karlidag T, Kaygusuz I, et al. The role of insulin-like growth factor I–II receptor on development of pleomorphic adenoma. Eur Arch Oto-Rhino- Laryngology. 2017;274(9):3443–7.
Neal MEH, Gensterblum-miller E, Bhangale AD, Kulkarni A, Zhai J, Smith J, et al. Integrative sequencing discovers an ATF1-motif enriched molecular signature that diff erentiates hyalinizing clear cell carcinoma from mucoepidemoid carcinoma. Oral Oncol [Internet]. 2021;117(November 2020):105270. Available from: https://doi.org/10.1016/j.oraloncology.2021.105270
Ahn MY, Ahn JW, Kim HS, Lee J, Yoon JH. Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells. Oncol Rep. 2015;33(4):1899–907.
Morassi M, Scavuzzo A, Cobelli M, Liserre B, Arias JA, Biasi B Di. Late intracranial metastasis from adenoid-cystic carcinoma of the parotid gland: Imaging, histologic and molecular features. 2020;(xxxx):1–6.
Andersson MK, Afshari MK, Andrén Y, Wick MJ, Stenman G. Targeting the Oncogenic ranscriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling. J Natl Cancer Inst. 2017;109(9):1–10.
Sahara S, Herzog AE, Nör JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res [Internet]. 2021;11(9):4092–110. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34659878%0Ahttp://www.pubmedcentral.nih.gov/article render.fcgi?artid=PMC8493384
Adenoma E, Suzuki T, Kano S, Suzuki M, Yasukawa S. Enhanced Angiogenesis in Salivary Duct Carcinoma. 2021;10(February):1–12.
Chooback N, Shen Y, Jones M, Kasaian K, Martin M, Ng T, et al. Carcinoma ex pleomorphic adenoma : case report and options for systemic therapy. 2017;24(3):251–4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mehreen Malik, Sadaf Alam, Sara Ziaullah, Maria Hanif, Noor Jahanzeb ; Ayesha Khitab
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
Share-copy and redistribute the material in any medium or format.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Attribution-You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial-You may not use the material for commercial purposes.
NoDerivatives-If you remix, transform, or build upon the material, you may not distribute the modified material.
No additional restrictions-You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
